BYSI — Beyondspring Share Price
Last trade - 00:00- $64.51m
- $80.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.56% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.18 | 1.35 | 1.35 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Directors
- Huang Lan CHM (50)
- Elizabeth Czerepak CFO (65)
- Richard Daly COO (60)
- Ramon Mohanlal EVP (62)
- G. Kenneth Lloyd CSO (77)
- Gordon Schooley OTH (74)
- Brendan Delaney DRC (46)
- Ravindra Majeti DRC (48)
- Patrick Fabbio IND (54)
- Matthew Kirkby IND (52)
- Quanqi Song IND (56)
- Jeffrey Vacirca IND (52)
- Yanbin Xie IND (62)
- Daniel Zabrowski IND (61)
- Ying Zhao IND (48)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 21st, 2014
- Public Since
- March 9th, 2017
- No. of Shareholders
- 67
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 40,316,320
- Address
- 100 Campus Drive, FLORHAM PARK, 07932
- Web
- https://www.beyondspringpharma.com/en/
- Phone
- +1 6465284184
- Auditors
- Marcum LLP
Upcoming Events for BYSI
Similar to BYSI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 19:33 UTC, shares in Beyondspring are trading at $1.60. This share price information is delayed by 15 minutes.
Shares in Beyondspring last closed at $1.60 and the price had moved by -29.52% over the past 365 days. In terms of relative price strength the Beyondspring share price has underperformed the S&P500 Index by -34.94% over the past year.
The overall consensus recommendation for Beyondspring is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBeyondspring does not currently pay a dividend.
Beyondspring does not currently pay a dividend.
Beyondspring does not currently pay a dividend.
To buy shares in Beyondspring you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.60, shares in Beyondspring had a market capitalisation of $64.51m.
Here are the trading details for Beyondspring:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BYSI
Based on an overall assessment of its quality, value and momentum Beyondspring is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Beyondspring is $1.25. That is 21.88% below the last closing price of $1.60.
Analysts covering Beyondspring currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beyondspring. Over the past six months, its share price has underperformed the S&P500 Index by -25.38%.
As of the last closing price of $1.60, shares in Beyondspring were trading -13.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beyondspring PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Beyondspring's management team is headed by:
- Huang Lan - CHM
- Elizabeth Czerepak - CFO
- Richard Daly - COO
- Ramon Mohanlal - EVP
- G. Kenneth Lloyd - CSO
- Gordon Schooley - OTH
- Brendan Delaney - DRC
- Ravindra Majeti - DRC
- Patrick Fabbio - IND
- Matthew Kirkby - IND
- Quanqi Song - IND
- Jeffrey Vacirca - IND
- Yanbin Xie - IND
- Daniel Zabrowski - IND
- Ying Zhao - IND